Net Loss Per Share

3 Months Ended

Mar. 31, 2023

The numerators and denominators of the basic and diluted net loss per share are computed as follows (in thousands, except per share, unit and per unit data):


	Three Months Ended March 31,
Basic and diluted net loss per share	2023		2022
Numerator:
Net loss	$	(26,214)	$	(18,825)
Denominator:
Weighted average shares outstanding—basic and diluted	138,548,599		131,882,556
Basic and diluted net loss per Share	$	(0.19)	$	(0.14)

As of March 31, 2023, there were outstanding Stock Options to purchase 4,936,049 shares of common stock at a weighted-average exercise price of $2.39, outstanding private warrants and public warrants to convert to 174,894 shares and 12,150,878 shares, respectively, of common stock at a price of $11.50 per share, outstanding PIPE warrants to convert to 13,888,889 shares of common stock at a price of $2.39 per share, convertible notes to convert to 18,844,600 shares of common stock at a conversion price of $10.61, ESPP contributions for the option to acquire 2,667,501 shares of common stock, and outstanding restricted stock units and performance stock units representing the right to receive 12,882,588 shares and 1,308,026 shares of common stock, respectively. Because of the net loss incurred during the three months ended March 31, 2023, the impacts of dilutive instruments would have been anti-dilutive for the period presented and have been excluded from loss per share calculations.

As of March 31, 2022, there were outstanding Stock Options to purchase 893,986 shares of common stock at an exercise price of $8.57, outstanding private warrants and public warrants to convert to 366,533 shares and 11,959,939 shares, respectively, of common stock at a price of $11.50 per share, convertible notes to convert to 17,931,304 shares of common stock at an initial conversion price of $11.50, and outstanding restricted stock units and performance stock units representing the right to receive 3,148,274 shares and 150,000 shares of common stock, respectively. Because of the net loss incurred during the three months ended March 31, 2022, the impacts of dilutive instruments would have been anti-dilutive for the period presented and have been excluded from loss per share calculations.